Prognostic Value of Pulmonary Transit Time by Cardiac Magnetic Resonance on Mortality and Heart Failure Hospitalization in Patients With Advanced Heart Failure and Reduced Ejection Fraction.


Journal

Circulation. Cardiovascular imaging
ISSN: 1942-0080
Titre abrégé: Circ Cardiovasc Imaging
Pays: United States
ID NLM: 101479935

Informations de publication

Date de publication:
01 2021
Historique:
pubmed: 14 1 2021
medline: 27 7 2021
entrez: 13 1 2021
Statut: ppublish

Résumé

Pulmonary transit time (PTT) from first-pass perfusion imaging is a novel parameter to evaluate hemodynamic congestion by cardiac magnetic resonance (cMR). We sought to evaluate the additional prognostic value of PTT in heart failure with reduced ejection fraction over other well-validated predictors of risk including the Meta-Analysis Global Group in Chronic Heart Failure risk score and ischemic cause. We prospectively followed 410 patients with chronic heart failure with reduced ejection fraction (61±13 years, left ventricular (LV) ejection fraction 24±7%) who underwent a clinical cMR to assess the prognostic value of PTT for a primary endpoint of overall mortality and secondary composite endpoint of cardiovascular death and heart failure hospitalization. Normal reference values of PTT were evaluated in a population of 40 asymptomatic volunteers free of cardiovascular disease. Results PTT was significantly increased in patients with heart failure with reduced ejection fraction as compared to controls (9±6 beats and 7±2 beats, respectively, Despite limitations in temporal resolution, PTT derived from first-pass perfusion imaging provides higher and independent prognostic information in heart failure with reduced ejection fraction than clinical and other cMR parameters, including LV and RV ejection fraction or feature tracking global longitudinal strain. Registration: URL: https://www.clinicaltrials.gov; Unique identifier: NCT03969394.

Sections du résumé

BACKGROUND
Pulmonary transit time (PTT) from first-pass perfusion imaging is a novel parameter to evaluate hemodynamic congestion by cardiac magnetic resonance (cMR). We sought to evaluate the additional prognostic value of PTT in heart failure with reduced ejection fraction over other well-validated predictors of risk including the Meta-Analysis Global Group in Chronic Heart Failure risk score and ischemic cause.
METHODS
We prospectively followed 410 patients with chronic heart failure with reduced ejection fraction (61±13 years, left ventricular (LV) ejection fraction 24±7%) who underwent a clinical cMR to assess the prognostic value of PTT for a primary endpoint of overall mortality and secondary composite endpoint of cardiovascular death and heart failure hospitalization. Normal reference values of PTT were evaluated in a population of 40 asymptomatic volunteers free of cardiovascular disease. Results PTT was significantly increased in patients with heart failure with reduced ejection fraction as compared to controls (9±6 beats and 7±2 beats, respectively,
CONCLUSIONS
Despite limitations in temporal resolution, PTT derived from first-pass perfusion imaging provides higher and independent prognostic information in heart failure with reduced ejection fraction than clinical and other cMR parameters, including LV and RV ejection fraction or feature tracking global longitudinal strain. Registration: URL: https://www.clinicaltrials.gov; Unique identifier: NCT03969394.

Identifiants

pubmed: 33438438
doi: 10.1161/CIRCIMAGING.120.011680
doi:

Banques de données

ClinicalTrials.gov
['NCT03969394']

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e011680

Auteurs

Laura Houard (L)

Division of Cardiology, Department of Cardiovascular Diseases, Cliniques Universitaires St. Luc (L.H., M.S.A., G.C., S.M., M.F.R., S.A.A., J.-L.J.V., A.-C.P., B.L.G.).
Pôle de Recherche Cardiovasculaire (CARD), Institut de Recherche Expérimentale et Clinique (IREC), Université Catholique de Louvain, Brussels, Belgium (L.H., M.S.A., S.M., M.F.R., S.A.A., J.-L.J.V., A.-C.P., B.L.G.).

Mihaela S Amzulescu (MS)

Division of Cardiology, Department of Cardiovascular Diseases, Cliniques Universitaires St. Luc (L.H., M.S.A., G.C., S.M., M.F.R., S.A.A., J.-L.J.V., A.-C.P., B.L.G.).
Pôle de Recherche Cardiovasculaire (CARD), Institut de Recherche Expérimentale et Clinique (IREC), Université Catholique de Louvain, Brussels, Belgium (L.H., M.S.A., S.M., M.F.R., S.A.A., J.-L.J.V., A.-C.P., B.L.G.).

Geoffrey Colin (G)

Division of Cardiology, Department of Cardiovascular Diseases, Cliniques Universitaires St. Luc (L.H., M.S.A., G.C., S.M., M.F.R., S.A.A., J.-L.J.V., A.-C.P., B.L.G.).

Helene Langet (H)

Philips Clinical Research Board, Suresnes, France (H.L.).

Sebastian Militaru (S)

Division of Cardiology, Department of Cardiovascular Diseases, Cliniques Universitaires St. Luc (L.H., M.S.A., G.C., S.M., M.F.R., S.A.A., J.-L.J.V., A.-C.P., B.L.G.).
Pôle de Recherche Cardiovasculaire (CARD), Institut de Recherche Expérimentale et Clinique (IREC), Université Catholique de Louvain, Brussels, Belgium (L.H., M.S.A., S.M., M.F.R., S.A.A., J.-L.J.V., A.-C.P., B.L.G.).

Michel F Rousseau (MF)

Division of Cardiology, Department of Cardiovascular Diseases, Cliniques Universitaires St. Luc (L.H., M.S.A., G.C., S.M., M.F.R., S.A.A., J.-L.J.V., A.-C.P., B.L.G.).
Pôle de Recherche Cardiovasculaire (CARD), Institut de Recherche Expérimentale et Clinique (IREC), Université Catholique de Louvain, Brussels, Belgium (L.H., M.S.A., S.M., M.F.R., S.A.A., J.-L.J.V., A.-C.P., B.L.G.).

Sylvie A Ahn (SA)

Division of Cardiology, Department of Cardiovascular Diseases, Cliniques Universitaires St. Luc (L.H., M.S.A., G.C., S.M., M.F.R., S.A.A., J.-L.J.V., A.-C.P., B.L.G.).
Pôle de Recherche Cardiovasculaire (CARD), Institut de Recherche Expérimentale et Clinique (IREC), Université Catholique de Louvain, Brussels, Belgium (L.H., M.S.A., S.M., M.F.R., S.A.A., J.-L.J.V., A.-C.P., B.L.G.).

Jean-Louis J Vanoverschelde (JJ)

Division of Cardiology, Department of Cardiovascular Diseases, Cliniques Universitaires St. Luc (L.H., M.S.A., G.C., S.M., M.F.R., S.A.A., J.-L.J.V., A.-C.P., B.L.G.).
Pôle de Recherche Cardiovasculaire (CARD), Institut de Recherche Expérimentale et Clinique (IREC), Université Catholique de Louvain, Brussels, Belgium (L.H., M.S.A., S.M., M.F.R., S.A.A., J.-L.J.V., A.-C.P., B.L.G.).

Anne-Catherine Pouleur (AC)

Division of Cardiology, Department of Cardiovascular Diseases, Cliniques Universitaires St. Luc (L.H., M.S.A., G.C., S.M., M.F.R., S.A.A., J.-L.J.V., A.-C.P., B.L.G.).
Pôle de Recherche Cardiovasculaire (CARD), Institut de Recherche Expérimentale et Clinique (IREC), Université Catholique de Louvain, Brussels, Belgium (L.H., M.S.A., S.M., M.F.R., S.A.A., J.-L.J.V., A.-C.P., B.L.G.).

Bernhard L Gerber (BL)

Division of Cardiology, Department of Cardiovascular Diseases, Cliniques Universitaires St. Luc (L.H., M.S.A., G.C., S.M., M.F.R., S.A.A., J.-L.J.V., A.-C.P., B.L.G.).
Pôle de Recherche Cardiovasculaire (CARD), Institut de Recherche Expérimentale et Clinique (IREC), Université Catholique de Louvain, Brussels, Belgium (L.H., M.S.A., S.M., M.F.R., S.A.A., J.-L.J.V., A.-C.P., B.L.G.).

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH